CORRESP Filing
CNS Pharmaceuticals, Inc.
Date: May 12, 2025 · CIK: 0001729427 · Accession: 0001683168-25-003394
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286529
Letter
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
May 12, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended (the "Registration Statement")
File No. 333-286529
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 9:30 A.M. (Eastern Time) on May 13, 2025, or as soon thereafter as possible on such date.
We request that we be notified of such effectiveness by a telephone call to Cavas Pavri at (202) 724-6847 of ArentFox Schiff LLP, and we request that such effectiveness also be confirmed in writing.
Very truly yours,
CNS Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 May 12, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended (the "Registration Statement") File No. 333-286529 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 9:30 A.M. (Eastern Time) on May 13, 2025, or as soon thereafter as possible on such date. We request that we be notified of such effectiveness by a telephone call to Cavas Pavri at (202) 724-6847 of ArentFox Schiff LLP, and we request that such effectiveness also be confirmed in writing. Very truly yours, CNS Pharmaceuticals, Inc. By: /s/ Christopher Downs Name: Christopher Downs Title: Chief Financial Officer cc: Cavas Pavri, ArentFox Schiff LLP